跳至主要内容
临床试验/ITMCTR2024000136
ITMCTR2024000136尚未招募Unknown

Research on the mechanism of Strengthening Spleen and Invigorating Qi therapy in improving skeletal muscle injury of Myasthenia Gravis based on ferroptosis regulated via O-GlcNAcylation modifying PRDX2/MFN2/ACSL4 signaling axis

The First Affiliated Hospital of Guangzhou University of Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
Unknown
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 75(—)
性别
All

入选标准

  • Inclusion criteria for MG patients:
  • 1) Age between 18-75 years old, male and female;
  • 2) Referring to the MG diagnostic criteria of the 2020 Chinese Guidelines for the Diagnosis and Treatment of Myasthenia Gravis, and according to the clinical typing of the Myasthenia Gravis Foundation of America (MGFA), patients with MG type II were selected as the study subjects;
  • 3) Using the above diagnosis as the first diagnosis for admission;
  • 4) Those who were not admitted with MG as the first diagnosis, but had a history of MG and whose first diagnosis was closely related to the recurrence, exacerbation, and treatment of MG (e.g., infection, etc.);
  • 5) Complete clinical history data;
  • 6) Agree to participate in this study and sign the informed consent form.
  • 2. Healthy volunteers inclusion criteria:
  • 1) Age between 18-75 years old, male and female;
  • 2) No history of MG;
  • 3) Agree to participate in this study and sign the informed consent.

排除标准

  • 1) Those whose first diagnosis on admission was not MG and whose reason for hospitalization was not related to MG recurrence, exacerbation, or treatment;
  • 2) Those with incomplete clinical history data;
  • 3) Those who combine other systematic serious diseases, such as psychiatric diseases, cerebrovascular diseases, cardiac, hepatic and renal failure, malignant tumors, etc.
  • 4) Congenital and family hereditary myasthenia gravis, myasthenia gravis crisis;
  • 5) Combined rheumatic, human immunodeficiency virus and other autoimmune diseases;
  • 6) Patients have participated in other clinical studies in the past month;
  • 7) Treatment with plasma exchange or intravenous gammaglobulin within the past 3 months;
  • 8) Pregnant or lactating women, or those of childbearing potential who are unwilling/unable to use effective contraception.

研究者

发起方
The First Affiliated Hospital of Guangzhou University of Chinese Medicine

相似试验